Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Novo Nordisk

Investors grow anxious at Novo Nordisk's silence over CagriSema weight loss results

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Fortune

Hims & Hers Super Bowl ad slams pricey pharma industry—and fumbles FDA warnings on compounded GLP-1 drugs

Taking a compounded GLP-1 medication isn’t the same thing as your pharmacy filling a cheaper, generic version of the drug your doctor prescribed.

Fortune

A cautionary tale that Europe can't afford to ignore

From giant to shadow: When do European juggernauts like Novo Nordisk and Nokia become too big to fail?

Fortune

From analysis to the latest developments in health,
read the most diverse news in one place.

Stricter abortion laws may cause increased infant deaths − 2 maternal and child health researchers explain the data

Infant mortality in the U.S. has increased by 7% since the 2022 Dobbs v. Jackson U.S. Supreme Court decision overturned the constitutional right to abortion, according to an October 2024 study.

The Conversation

Apple, Nvidia, and more of the 2025 World's Most Admired Companies

Plus: How AI propelled Nvidia up the list and other insights from this year's survey of corporate reputations.

Fortune

This country approves Ozempic to reduce risk of kidney disease in diabetes patients

The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with chronic kidney disease (CKD).

The Times of India

This Little-Known Stock Just Doubled on Weight-Loss Drug News. Analysts Think It Has 400% Upside Potential From Here.

This weight-loss underdog doubled in a single day last week and could deliver even bigger rewards.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Why isn’t Ozempic on Australia’s Pharmaceutical Benefits Scheme for weight loss? And should it be?

The drug is subsidised for treatment of type 2 diabetes but experts say it could help reduce other health problems associated with severe obesity

The Guardian - AU

Wegovy maker Novo Nordisk rebuked by watchdog over failure to disclose payments to UK health groups

Danish drug giant found to have failed to accurately report spending even after admitting to errors

The Guardian - UK

‘Skinny jabs’ are turning slimmers teetotal – and drinks companies are feeling the loss

As the public rejoice at shedding weight, the likes of Wegovy seem to be controlling other bad habits – in particular drinking to excess

The Guardian - UK

Novo Nordisk stock surges 7% on new weight-loss drug update

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger.

Fortune

Novo Nordisk Stock Surges On Weight Loss Drug Data and Analysts Say It's Still a Buy

Novo Nordisk stock is paring its year-over-year deficit on positive early stage trial results for the company's new weight loss drug. Here's what you need to know.

Kiplinger

Ultrasound Weight Loss: GE HealthCare and Novo Nordisk’s Play

GLP-1 drugs have been all the rage for weight loss, but GE Healthcare and Novo Nordisk are working on a non-invasive approach to controlling metabolic functions

MarketBeat

LVMH dethrones Novo Nordisk as Europe's most valuable company

Novo Nordisk has faced a massive selloff in recent months amid disappointing drug trials and U.S. pressure to cut its prices.

Fortune

Get all your
news in one place.

100's of premium titles.
One news app.

Fortune

Novo Nordisk CEO attends crisis talks with Danish PM amid Trump's Greenland threats

Bosses from Fortune 500 Europe companies including Novo Nordisk, Lego, and Carlsberg met with the PM as Trump ups his threats over Greenland.

The Conversation

How we diagnose and define obesity is set to change – here’s why, and what it means for treatment

Obesity is linked to many common diseases, such as type 2 diabetes, heart disease, fatty liver disease and knee osteoarthritis.

Barchart

Trump Wants Greenland. Why That Could Be Bad News for Novo Nordisk Stock.

The pharma giant’s stock has been under pressure since the Greenland issue has been in the spotlight.

Top News

FDA Approves Generic Version Of Diabetes Drug Liraglutide

FDA approves generic liraglutide for type 2 diabetes, offering affordability and addressing shortage.

Fortune

Novo Nordisk faces stock market bloodbath after drug trial disappoints

Shares in Novo Nordisk plunged 20% on Friday.

International Business Times

Ozempic May Face Investigation Over Vision-Threatening Condition In Some Patients

Danish health authorities asked the European Union to review two studies linking Novo Nordisk's diabetes drug, Ozempic, to a rare eye condition.

MarketBeat

Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon

Novo Nordisk A/S is moving closer to adding more sales for its blockbuster GLP-1 drug semaglutide to treat a chronic liver disease.

1 … 15 16 17 18

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.